



## Cathryn R. Nagler, PhD

*University of Chicago*

Biological Sciences Division and Pritzker School of Molecular Engineering

### AREA(S) OF FOCUS:

#### Understanding the role of the gut microbiome in health and disease

The Nagler lab is using preclinical models to identify unique features of gut bacteria communities contributing to intestinal function and food allergy.

### KEY RESEARCH AREAS:

#### Food allergy


Identify mechanisms underlying the regulation of the bacterial gut microbiome and susceptibility to food allergy.

#### Microbiome-modulating therapies

Encourage a healthy microbiome to restore and maintain intestinal barrier integrity.

#### Gut immune system

Study immune system regulatory mechanisms and their response to external stimuli.



### ENTREPRENEURIAL SUCCESS:



ClostraBio is developing novel ways to treat inflammatory bowel disease and food allergies using compounds naturally produced by bacteria in the gut.

ClostraBio's technology uses co-polymers to effectively deliver butyrate, a simple compound produced by gut bacteria, to help individuals with life-threatening food allergies.

Development of new therapeutic modalities to target the immune response in mild-to-moderate ulcerative colitis is also an interest of ClostraBio.

Series A (2022) - \$4 million and raised \$11 million overall.

Located at Portal innovations as a portfolio company.